FibroGen's stock price increase following the Q1 earnings report is attributed to its sales outperformance and optimistic future projections. Despite the earnings miss, the significant sales growth, especially from roxadustat in China, and the positive developments in drug trials present a strong case for potential short-term positive impact on the stock. The detailed financial health and strategic advancements, including a cash runway into 2026, further bolster investor confidence.